Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. [electronic resource]
Producer: 20200618Description: 2895-2909 p. digitalISSN:- 1865-8652
- Aged
- Aged, 80 and over
- Benzhydryl Compounds -- adverse effects
- Canagliflozin -- adverse effects
- Cardiovascular Diseases -- chemically induced
- Cross-Sectional Studies
- Diabetes Mellitus, Type 2 -- drug therapy
- Female
- Glucosides -- adverse effects
- Humans
- Hypoglycemic Agents -- adverse effects
- Male
- Middle Aged
- Sodium-Glucose Transporter 2 -- drug effects
- Sodium-Glucose Transporter 2 Inhibitors -- adverse effects
- United States
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.